Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Genitourinary 1Dermatologic 1

Conditions

Prostatic Neoplasms 3Neoplasms 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma 1

Interventions

Cyclophosphamide 8pembrolizumab 6Filgrastim 5Busulfan 5fludarabine phosphate 4fludarabine 4Nivolumab 4Flow Cytometry 4Antilymphocyte Serum 4Alemtuzumab 4Tacrolimus 3Stem Cell Transplantation 3Sirolimus 3Radiotherapy 3Peripheral Blood Stem Cell Transplantation 3Paclitaxel 3Mycophenolic Acid 3Melphalan 3Dexamethasone 3Carboplatin 3Biopsy 3Azacitidine 3valspodar 2atezolizumab 2aldesleukin 2X-Rays 2Vorinostat 2Vincristine 2Thiotepa 2Psychiatric Rehabilitation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × sepantronium × Genitourinary × Clear all
NCT00818480 2015-09-04

An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155

Astellas Pharma Inc

Phase 2 Completed
10 enrolled
DermatologicGenitourinaryLymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Melanoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡